Active substance
Erythromycin
- SFDA 25
- US FDA 90
- Health Canada 5
- US price lines 14
- NHS prices 3
- WHO EML 2
- Safety 6
SFDA Saudi Arabia — SFDA human drug list
| Trade name | Strength | Form · route | Pack | Public price | Type | Company | Status |
|---|---|---|---|---|---|---|---|
| EROMYCIN 200MG-5ML SUSP | 40 mg/ml | Granules for oral suspension · Oral use | 1 Bottle | SAR 15.55 | Generic · Prescription | Gulf Pharmaceutical Industries (Julphar) | Valid |
| ERYTHRODAR | 250 mg | Coated tablet · Oral use | 20 Blister | SAR 7.55 | Generic · Prescription | DAR ALDAWA | Valid |
| ERYTHRODAR 400MG FORT TAB | 400 mg | Film-coated tablet · Oral use | 20 Blister | SAR 10.25 | Generic · Prescription | DAR ALDAWA | Valid |
| OMATHROCIN 200 ORAL SUSPENSION | 40 mg/ml | Suspension · Oral use | 1 Bottle | SAR 7.05 | Generic · Prescription | National Pharmaceutical Industries Co. (SAOG) | Valid |
| OMATHROCIN 250 MG TABLET | 250 mg | Tablet · Oral use | 20 Blister | SAR 9.95 | Generic · Prescription | National Pharmaceutical Industries Co. (SAOG) | Valid |
| OMATHROCIN ORAL DROPS 100 MG- 2.5 ML | 40 mg/ml | Oral drops · Oral use | 1 Bottle | SAR 4.40 | Generic · Prescription | National Pharmaceutical Industries Co. (SAOG) | Valid |
| EROMYCIN 250MG TABLET | 250 mg | Film-coated tablet · Oral use | 20 Blister | SAR 11.05 | Generic · Prescription | Gulf Pharmaceutical Industries (Julphar) | Withdrawn by MAH · Not Marketed |
| ERYC 250MG CAPS | 250 mg | Capsule · Oral use | 20 Blister | SAR 25.75 | Generic · Prescription | F.H. FAULDING | Withdrawn by MAH · Not Marketed |
| ERYDERM FOR TOPICAL SOLN 2% | 2 % | Cutaneous solution · Topical | 1 Bottle | SAR 32.50 | NCE · Prescription | Abbott Laboratories | Withdrawn by MAH · Not Marketed |
| ERYPED FOR ORAL SOLN 400MG-5ML | 80 mg/ml | Oral solution · Oral use | 1 Bottle | SAR 26.65 | Generic · Prescription | Abbott Laboratories | Withdrawn by MAH · Not Marketed |
| ERYSOL 2% TOPICAL LOTION | 2 % | Lotion · Topical | 1 Bottle | SAR 22.75 | Generic · Prescription | Dallah Pharma Factory | Withdrawn by MAH · Not Marketed |
| ERYTHROCIN GRANULES 200MG-5ML | 40 mg/ml | Oral suspension · Oral use | 1 Bottle | SAR 14.40 | NCE · Prescription | Abbott Laboratories | Withdrawn by MAH · Not Marketed |
| ERYTHROCIN GRANULES 200MG-5ML | 40 mg/ml | Oral suspension · Oral use | 1 Bottle | SAR 19.45 | Generic · Prescription | Abbott Laboratories | Withdrawn by MAH · Not Marketed |
| ERYTHROCIN I.V. 1G VIAL | 1 g | Injection · Intravenous use | 1 Vial | SAR 41.55 | NCE · Prescription | Abbott Laboratories | Withdrawn by MAH · Not Marketed |
| ERYTHROCIN I.V. 500MG VIAL | 500 mg | Injection · Intravenous use | 1 Vial | SAR 22.90 | NCE · Prescription | Abbott Laboratories | Withdrawn by MAH · Not Marketed |
| ERYTHROCIN PCE 333MG TAB | 333 mg | Tablet · Oral use | 20 Blister | SAR 29.90 | Generic · Prescription | Abbott Laboratories | Withdrawn by MAH · Not Marketed |
| ERYTHROCIN TAB. 250 MG. | 250 mg | Tablet · Oral use | 20 Blister | SAR 13.80 | NCE · Prescription | Abbott Laboratories | Withdrawn by MAH · Not Marketed |
| ERYTHROCIN TAB. 500MG. | 500 mg | Tablet · Oral use | 20 Blister | SAR 22.10 | Generic · Prescription | Abbott Laboratories | Withdrawn by MAH · Not Marketed |
| ERYTHRODAR | 40 mg/ml | Oral suspension · Oral use | 1 Bottle | SAR 6.20 | Generic · Prescription | DAR ALDAWA | Withdrawn by MAH · Not Marketed |
| ERYTHROMIL 200MG-5ML SUSP. | 40 mg/ml | Suspension · Oral use | 1 Bottle | SAR 6.20 | Generic · Prescription | APM | Withdrawn by MAH · Not Marketed |
| ERYTHROMIL 250MG TAB | 250 mg | Film-coated tablet · Oral use | 20 Blister | SAR 7.55 | Generic · Prescription | APM | Withdrawn by MAH · Not Marketed |
| ERYTHROMIL FORTE 400MG-5MLSUSP. | 80 mg/ml | Suspension · Oral use | 1 Bottle | SAR 9.35 | Generic · Prescription | APM | Withdrawn by MAH · Not Marketed |
| ERYTHROMYCIN LACTOBIONATE 1G IV VIAL | 1 g | Solution · Intravenous use | 1 Vial | SAR 36.15 | Generic · Prescription | HOSPIRA AUSTRALIA | Withdrawn by MAH · Not Marketed |
| OFTALMOLOSA 0.5% | 0.5 % | Eye ointment · Ocular use | 1 Tube | SAR 7.35 | NCE · Prescription | ALCON CUSI | Withdrawn by MAH · Not Marketed |
| RYTHINATE SUSP. 200MG-5ML | 40 mg/ml | Suspension · Oral use | 1 Bottle | SAR 6.00 | Generic · Prescription | Hikma Pharmaceuticals PLC | Invalid · Not Marketed |
Indications — CHI Daman Drug Formulary
ACUTE COUGH; ACUTE EXACERBATION OF BRONCHIECTASIS (NON-CYSTIC FIBROSIS)-LONG-TERM ORAL ANTIBIOTIC TREATMENT; ACUTE EXACERBATION OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD); BACTERIAL SKIN INFECTIONS - ERYSIPELAS AND CELLULITIS; BACTERIAL SKIN INFECTIONS - IMPETIGO AND ECTHYMA; BACTERIAL TONSILLOPHARYNGITIS TREATMENT AND PREVENTION; BACTRIAL INFECTIONS OF THE GASTROINTESTINAL TRACT - VIBRIO CHOLERAE; COMMUNITY ACQUIRED PNEUMONEA; MATERNAL AND CHILD HEALTHCARE- PROPHYLAXIS FOR P-PROM; MUCOPURULENT CONJUCTIVITIS - GONOCOCCAL INFECTION OF THE EYE - CHLAMYDIAL CONJUNCTIVITIS; OTITIS MEDIA; PHARYNGITIS; RENAL TRANSPLANT; SICKLE CELL DISEASE - ACS MANAGEMENT; SINUSITIS; TRAVEL RELATED INFECTIONS-TREATMENT
US FDA United States — FDA approvals (Drugs@FDA)
| Product | Strength | Form · route | Applicant | Status | First approved |
|---|---|---|---|---|---|
| ERYTHROMYCIN | 250MG; 500MG | tablet · oral | CARNEGIE | Prescription | 11 Jul 1972 |
| ERYC | 250MG | capsule, delayed rel pellets · oral | DR REDDYS LABS SA | Prescription | 26 Jan 1981 |
| ERY-TAB | 250MG; 500MG; 333MG | tablet, delayed release · oral | PHARMOBEDIENT | Prescription | 29 Mar 1982 |
| ERYTHROMYCIN | 250MG | capsule, delayed rel pellets · oral | PHARMOBEDIENT | Prescription | 22 Dec 1986 |
| ERYTHRA-DERM | 2% | solution · topical | MICRO LABS | Prescription | 5 Feb 1988 |
| ERYTHROMYCIN | 2% | solution · topical | PADAGIS US | Prescription | 11 Jan 1991 |
| ERYTHROMYCIN | 2% | gel · topical | PADAGIS US | Prescription | 29 Jan 1993 |
| ERYTHROMYCIN | 0.5% | ointment · ophthalmic | BAUSCH AND LOMB INC | Prescription | 29 Jul 1994 |
| ERYTHROMYCIN | 2% | swab · topical | PADAGIS US | Prescription | 3 Jul 1996 |
| ERYTHROMYCIN | 0.5% | ointment · ophthalmic | SENTISS | Prescription | 18 Jul 1996 |
| ERYTHROMYCIN | 2% | gel · topical | FOUGERA PHARMS | Prescription | 30 Sep 1997 |
| ERYTHROMYCIN | 2% | swab · topical | EPIC PHARMA LLC | Prescription | 12 May 2010 |
| ERYTHROMYCIN | 250MG; 333MG; 500MG | tablet, delayed release · oral | AMNEAL PHARMS CO | Prescription | 2 Jul 2019 |
| ERYTHROMYCIN | 250MG; 500MG | tablet · oral | TORRENT | Prescription | 6 Jul 2020 |
| ERYTHROMYCIN | 250MG; 500MG | tablet · oral | TEVA PHARMS USA INC | Prescription | 11 Feb 2021 |
| ERYTHROMYCIN | 250MG; 500MG | tablet · oral | CADILA PHARMS LTD | Prescription | 28 Jun 2021 |
| ERYTHROMYCIN | 250MG; 500MG; 333MG | tablet, delayed release · oral | TORRENT | Prescription | 26 Jul 2021 |
| ERYTHROMYCIN | 250MG; 500MG | tablet · oral | ALKEM LABS LTD | Prescription | 13 Jul 2022 |
| ERYTHROMYCIN | 250MG; 500MG | tablet · oral | ZYDUS LIFESCIENCES | Prescription | 7 Mar 2023 |
| ERYTHROMYCIN | 250MG; 500MG | tablet · oral | ALEMBIC | Prescription | 24 Aug 2023 |
| ERYTHROMYCIN | 250MG; 500MG | tablet · oral | ABON PHARMS LLC | Prescription | 23 Sep 2025 |
| ERYTHROCIN STEARATE | EQ 250MG BASE; EQ 125MG BASE; EQ 500MG BASE | tablet · oral | AZURITY | Discontinued | 24 Jun 1964 |
| ILOTYCIN | 0.5% **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | ointment · ophthalmic | DISTA | Discontinued | 29 Jun 1964 |
| ERYTHROMYCIN STEARATE | EQ 250MG BASE | tablet · oral | ANI PHARMS | Discontinued | 8 Sep 1972 |
| ERYTHROMYCIN STEARATE | EQ 250MG BASE; EQ 500MG BASE | tablet · oral | PHARMOBEDIENT | Discontinued | 16 Jan 1973 |
65 more — full table
Canada Canada — marketed products (Health Canada)
| Brand | DIN | Strength | Form · route | Company |
|---|---|---|---|---|
| ERYTHROCIN I.V. | 00682268 | 500 MG / VIAL | POWDER FOR SOLUTION · INTRAVENOUS | AMDIPHARM LIMITED |
| ERYTHROCIN I.V. | 00682276 | 1 G / VIAL | POWDER FOR SOLUTION · INTRAVENOUS | AMDIPHARM LIMITED |
| ERYTHROMYCIN | 02141574 | 5 MG / G | OINTMENT · OPHTHALMIC | PHARMA STULLN INC. |
| ERYTHROMYCIN OPHTHALMIC OINTMENT USP | 02326663 | 5 MG / G | OINTMENT · OPHTHALMIC | STERI-MED PHARMA INC. |
| PDP-ERYTHROMYCIN | 01912755 | 5 MG / G | OINTMENT · OPHTHALMIC | PENDOPHARM DIVISION OF PHARMASCIENCE INC |
Prices — United States and England
| Source | Product as listed | Price | Unit / pack | Date |
|---|---|---|---|---|
| US NADAC | ERYTHROMYCIN 0.5% EYE OINTMENT | $2.82657 | per GM | 23 Sep 2026 |
| US NADAC | ERYTHROMYCIN 0.5% EYE OINTMENT | $6.83399 | per GM | 23 Sep 2026 |
| US NADAC | ERYTHROMYCIN 2% GEL | $0.67256 | per GM | 23 Sep 2026 |
| US NADAC | ERYTHROMYCIN 2% GEL | $0.6827 | per GM | 23 Sep 2026 |
| US NADAC | ERYTHROMYCIN 2% SOLUTION | $0.35204 | per ML | 23 Sep 2026 |
| US NADAC | ERYTHROMYCIN 200 MG/5 ML SUSP | $0.91229 | per ML | 23 Sep 2026 |
| US NADAC | ERYTHROMYCIN 200 MG/5 ML SUSP | $1.52026 | per ML | 23 Sep 2026 |
| US NADAC | ERYTHROMYCIN 250 MG TABLET | $1.95521 | per EA | 23 Sep 2026 |
| US NADAC | ERYTHROMYCIN 400 MG/5 ML SUSP | $1.74359 | per ML | 23 Sep 2026 |
| US NADAC | ERYTHROMYCIN 500 MG TABLET | $2.51038 | per EA | 23 Sep 2026 |
| US NADAC | ERYTHROMYCIN DR 250 MG CAP | $5.95998 | per EA | 22 Apr 2026 |
| US NADAC | ERYTHROMYCIN DR 250 MG TABLET | $1.92505 | per EA | 23 Sep 2026 |
| NHS Drug Tariff | Erythromycin 250mg gastro-resistant tablets | £11.88 | 28 tablet | 1 Oct 2026 |
| NHS Drug Tariff | Erythromycin stearate 250mg tablets | £18.20 | 100 tablet | 1 Oct 2026 |
| NHS Drug Tariff | Erythromycin stearate 500mg tablets | £36.40 | 100 tablet | 1 Oct 2026 |
NADAC: average price US retail pharmacies pay to buy the medicine. NHS Drug Tariff Part VIIIA: basic price reimbursed to pharmacies in England and Wales.
WHO WHO Model List of Essential Medicines (2025)
- 6.2.2. Watch group antibiotics · core
Second choice: Therapeutic equivalent to clarithromycin for Acute pharyngitis - 21.1. Ophthalmological preparations > Anti-infective agents · core
Chlamydial conjunctivitis; Gonococcal infection of eye
Local > Ophthalmological > Ointment: 0.5% (EMLc)
Safety signals and safety-related labeling changes
- MHRA 17 Dec 2020 Erythromycin: caution required due to cardiac risks (QT interval prolongation); drug interaction with rivaroxaban
Erythromycin has been associated with events secondary to QT interval prolongation such as cardiac arrest and ventricular fibrillation. Erythromycin should not be given to patients with a history of QT interval prolongation or ventricular cardiac arrhythmia, including torsades de pointes, or patients with electrolyte disturbances. A potential drug interaction between rivaroxaban and erythromycin resulting in increased risk of bleeding has also been identified. - MHRA 17 Dec 2020 Erythromycin: update on known risk of infantile hypertrophic pyloric stenosis
Updates have been made to the magnitude of the known risk of infantile hypertrophic pyloric stenosis following exposure to erythromycin in infancy as a result of new epidemiological data. The risk is particularly increased in the first 14 days after birth. Weigh the benefit of erythromycin therapy in infants against the potential risk of infantile hypertrophic pyloric stenosis. - US FDA 23 Apr 2018 ERYC — safety-related labeling change
Labeling sections changed: Contraindications - US FDA 23 Apr 2018 PCE — safety-related labeling change
Labeling sections changed: Contraindications - EMA PRAC 29 Sep 2017 PRAC signal: Acute generalised exanthematous pustulosis (AGEP)
Action for MAH: update of the product information: Yes - EMA PRAC 5 May 2017 PRAC signal: Acute generalised exanthematous pustulosis (AGEP)
Action for MAH: update of the product information: No
Combinations containing Erythromycin
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.